Oban Biopharma
- Biotech or pharma, therapeutic R&D
Oban BioPharma, Inc. is focused on computational and AI-assisted approaches to discover next-generation allosteric/biased oral GPCR therapeutics for CNS and metabolic diseases. In CNS, Oban is advancing a series of proprietary, orally active, muscarinic M4 receptor Ago-PAMs (positive allosteric modulators with intrinsic agonist activity) for neuropsychiatric and neurological indications. Lead compounds exhibit potent allosteric and intrinsic agonist properties and best-in-class M4 selectivity, with no interaction with any other GPCRs, including the closely related M2 receptor, associated with adverse events. Lead M4 compounds exhibit dose-dependent activity in validated animal models of schizophrenia/psychosis comparable to the non-selective muscarinic agonist, xanomeline (COBENFY™ - FDA-approved, 2024). IND-enabling studies for a lead compound are in progress.
In the metabolic area, Oban is developing small molecule GPCR modulators which complement/mimic GLP-1-based approaches.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}